Healthcare Biz Cheat Sheet: Acura Wins Patent, Bristol-Myers Completes Treament for $2.9B Hep-C Drug

Acura Pharmaceuticals (NASDAQ:ACUR) shares continued to climb after the company announced it had won a key patent for its drug abuse deterrent formulation.

Hot Feature: Renewables Pushing Down Energy Prices

Genomic Health (NASDAQ:GHDX) shares climbed more than 10% today after the company announced that the national contractor for its Oncotype DX colon cancer testing product had established Medicare coverage for the product.

Human Genome Sciences (NASDAQ:HGSI) shares closed the day lower after reports that U.K. regulators are considering not providing coverage for its lupus drug Benlysta, which would be a controversial and unexpected move, given that the drug has already won approval in the U.S. and Europe.

Merck (NYSE:MRK) has freed itself up to offer more over-the-counter drugs by selling its interest in a joint venture with Johnson & Johnson (NYSE:JNJ).

Bristol-Myers (NYSE:BMY) is close to completing a treatment for Hepatitis C that could be launched by 2015 and bring in $2.9B in global sales within five years.

Don’t Miss: FBI Investigating Solyndra for Accounting Fraud

AstraZeneca (NYSE:AZN) has entered into a settlement with Handa Pharmaceuticals in a patent infringement case over the latter’s proposed Seroquel extended-release tablets. The settlement will allow Handa to enter the U.S. market with the durg in November 2016 or earlier.